Business Wire

PMI

10.10.2019 10:47:10 CEST | Business Wire | Press release

Share
PMI Sets Carbon Neutrality Target for All of Its Factories By 2030

Philip Morris International Inc. (PMI) (NYSE: PM) today announced its aim that all its factories become carbon neutral by 2030. The announcement comes as PMI celebrates its factory in Klaipeda, Lithuania, as its first carbon neutral manufacturing facility.

“A clear message emerged from last month’s Climate Week NYC, run in coordination with the UN General Assembly: Now is the time to act against climate change,” said Huub Savelkouls, PMI’s Chief Sustainability Officer. “We share the ambition of limiting global temperature rise to 1.5 degrees Celsius. This requires setting challenging targets, taking action to achieve them and transparently reporting on progress and gaps. This is what our employees, our consumers and our shareholders expect from us. Today is important for PMI, as we celebrate our first step toward carbon neutrality in all our factories by 2030.”

At its factory in Klaipeda, Lithuania, PMI has implemented multiple projects over the past 10 years to optimize its energy usage and reduce carbon emissions. This has included upgrading utilities equipment, such as chillers and compressors, and facilitating heat recovery to optimize fuel use for heating purposes; installing a biomass boiler; procuring certified renewable electricity and offsetting natural gas carbon emissions with biogas certificates. To offset the remaining carbon emissions, PMI invested in Gold Standard certificates from climate protection initiatives. These initiatives support more than 9,000 families in India by promoting domestic biogas production to replace kerosene and firewood as cooking fuels, contributing to a reduction in greenhouse gas emissions and deforestation.

“Reducing the environmental footprint of our operations is a priority for PMI,” said Massimo Andolina, PMI’s Senior Vice President Operations. “I am extremely proud of our first important milestone in Klaipeda, testament to our commitment to make all PMI manufacturing operations carbon neutral by 2030. We are focused on, committed to and motivated by this objective, and we will achieve it thanks to the passion of all our people, to the ongoing efforts to reduce our energy needs and conserve energy inside our factories, and also thanks to a number of focused investments aimed at making all our operations environmentally sound and sustainable for the future.”

PMI is also actively pursuing initiatives to address the pressing climate challenge beyond its operations. For example, it is working with farmers and suppliers across its tobacco supply chain to lower the greenhouse gas emissions in the tobacco curing process by 70 percent by 2020 (vs. 2010) and to achieve zero net deforestation of natural forest by 2025.

In 2019—for the fifth consecutive year—PMI achieved the top score (Climate A-List) from CDP, the global disclosure system that enables organizations to measure and manage greenhouse gas emissions and other impacts. As one of its environmental commitments, PMI has set and committed to science-based targets—greenhouse gas emissions levels that science acknowledges as tolerable for the planet—and to go beyond these in its operations by aiming for carbon neutrality by 2030.

About Sustainability at PMI

For Philip Morris International (PMI), sustainability is about replacing cigarettes with better alternatives, addressing sustainability challenges across its value chain and seizing opportunities to add value to society. It is an integral part of the company’s business strategy. PMI takes decisive actions in areas where its work can have the greatest impact, from the more than 350,000 farmers from which it sources tobacco right up to the approximately 150 million consumers of PMI products. To learn more, visit www.pmi.com/sustainability .

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is leading a transformation in the tobacco industry to create a smoke-free future and ultimately replace cigarettes with smoke-free products to the benefit of adults who would otherwise continue to smoke, society, the company and its shareholders. PMI is a leading international tobacco company engaged in the manufacture and sale of cigarettes, smoke-free products and associated electronic devices and accessories, and other nicotine-containing products in markets outside the U.S. PMI is building a future on a new category of smoke-free products that, while not risk free, are a much better choice than continuing to smoke. Through multidisciplinary capabilities in product development, state-of-the-art facilities and scientific substantiation, PMI aims to ensure that its smoke-free products meet adult consumer preferences and rigorous regulatory requirements. PMI’s smoke-free IQOS product portfolio includes heat-not-burn and nicotine-containing vapor products. As of June 30, 2019, PMI estimates that approximately 8.0 million adult smokers around the world have already stopped smoking and switched to PMI’s heat-not-burn product, available for sale in 48 markets in key cities or nationwide under the IQOS brand. For more information, please visit www.pmi.com and www.pmiscience.com .

# # #

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 13:32:00 CET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 09:00:00 CET | Press release

The Latest Players and AI Capabilities Drive Captivating, Personalized, and Interactive Signage With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerfu

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 08:30:00 CET | Press release

Iconic Vbeam® Pro and Matrix™ Systems showcased ahead of broader commercial availability Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, suppo

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 08:00:00 CET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye